Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Risk of serious infections and malignancies with anti-TNF antibody therapy in rheumatoid arthritis.

× No keyword cloud information.

8 in total

Review 1. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007.

Authors: D E Furst; F C Breedveld; J R Kalden; J S Smolen; G R Burmester; J Sieper; P Emery; E C Keystone; M H Schiff; P Mease; P L C M van Riel; R Fleischmann; M H Weisman; M E Weinblatt
Journal: Ann Rheum Dis Date: 2007-11 Impact factor: 19.103

Review 2. Malignancy risk of anti-tumor necrosis factor alpha blockers: an overview of systematic reviews and meta-analyses.

Authors: Yuehong Chen; Jianhong Sun; Yuan Yang; Yupeng Huang; Gang Liu
Journal: Clin Rheumatol Date: 2015-11-16 Impact factor: 2.980

Review 3. TNF-alpha and its inhibitors in cancer.

Authors: Inès Zidi; Souhir Mestiri; Aghleb Bartegi; Nidhal Ben Amor
Journal: Med Oncol Date: 2009-03-11 Impact factor: 3.064

4. Long-term risk of malignancy among patients treated with immunosuppressive agents for ocular inflammation: a critical assessment of the evidence.

Authors: John H Kempen; Sapna Gangaputra; Ebenezer Daniel; Grace A Levy-Clarke; Robert B Nussenblatt; James T Rosenbaum; Eric B Suhler; Jennifer E Thorne; C Stephen Foster; Douglas A Jabs; Kathy J Helzlsouer
Journal: Am J Ophthalmol Date: 2008-06-25 Impact factor: 5.258

Review 5. Malignancy and rheumatoid arthritis.

Authors: Johan Askling
Journal: Curr Rheumatol Rep Date: 2007-10 Impact factor: 4.592

Risk of serious infections and malignancies with anti-TNF antibody therapy in rheumatoid arthritis.

Review 1. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007.

Review 2. Malignancy risk of anti-tumor necrosis factor alpha blockers: an overview of systematic reviews and meta-analyses.

Review 3. TNF-alpha and its inhibitors in cancer.

4. Long-term risk of malignancy among patients treated with immunosuppressive agents for ocular inflammation: a critical assessment of the evidence.

Review 5. Malignancy and rheumatoid arthritis.

Review 6. Treating rheumatic patients with a malignancy.

7. The safety of systemic treatments that can be used for geriatric psoriasis patients: a review.

8. Update on the use of etanercept across a spectrum of rheumatoid disorders.